ArticleJournal of clinical laboratory analysis2026
Integrating Prostate-Specific Antigen Density and Prostate Imaging Reporting and Data System Scores to Optimize Detection of Clinically Significant Prostate Cancer: A Multivariable Risk Model Approach.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrebiopsy multiparametric MRI (mpMRI) reported using the Prostate Imaging Reporting and Data System (PI-RADS) improves prostate cancer triage, yet false-positive findings remain common and may drive unnecessary biopsy. Prostate-specific antigen density (PSAD) is an inexpensive laboratory-derived adjunct that may refine MRI-based risk stratification.
methodsWe retrospectively screened 713 transrectal ultrasound (TRUS)-guided biopsy episodes from a single experienced urologist's practice at a tertiary referral hospital between October 2022 and August 2025 and included 375 men with prebiopsy mpMRI reported using PI-RADS version 2.1 and complete data for prespecified predictors. All patients underwent systematic 12-core TRUS-guided biopsy. Clinically significant prostate cancer (csPCa) was defined as International Society of Urological Pathology (ISUP) grade group ≥ 2. We developed logistic regression models combining PSAD and PI-RADS (parsimonious model) and adding age and digital rectal examination (DRE) (full model). Discrimination (AUC), calibration, and clinical utility (decision curve analysis) were assessed, and the incremental value of PSAD beyond PI-RADS for csPCa was quantified using IDI and continuous NRI.
resultscsPCa was present in 93/375 (24.8%) and any prostate cancer in 144/375 (38.4%). For csPCa prediction, AUC was 0.746 for PI-RADS and 0.760 for PSAD; the combined PSAD+PI-RADS model achieved AUC 0.798 and the full model AUC 0.794. Adding PSAD to PI-RADS improved IDI (0.0528; p < 0.001) and total continuous NRI (0.3926; p < 0.001), driven mainly by improved down-classification of non-csPCa cases.
conclusionsIntegrating PSAD with PI-RADS improved csPCa risk stratification compared with PI-RADS alone, with predominant benefit as a biopsy-sparing, rule-out adjunct. External validation is required for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.